Literature DB >> 20380156

Expression profiling and putative mechanisms of resistance to doxorubicin of human lung cancer cells.

K N Kashkin1, E A Musatkina, A V Komelkov, I A Favorskaya, E V Trushkin, V A Shleptsova, D A Sakharov, T V Vinogradova, E P Kopantzev, M V Zinovyeva, O V Kovaleva, I B Zborovskaya, A G Tonevitsky, E D Sverdlov.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20380156     DOI： 10.1134/s1607672910010072

Source DB:  PubMed          Journal:  Dokl Biochem Biophys        ISSN： 1607-6729            Impact factor:   0.788


× No keyword cloud information.
  15 in total

1.  Chemosensitivity prediction by transcriptional profiling.

Authors:  J E Staunton; D K Slonim; H A Coller; P Tamayo; M J Angelo; J Park; U Scherf; J K Lee; W O Reinhold; J N Weinstein; J P Mesirov; E S Lander; T R Golub
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

Review 2.  Cellular mechanisms of multidrug resistance of tumor cells.

Authors:  A A Stavrovskaya
Journal:  Biochemistry (Mosc)       Date:  2000-01       Impact factor: 2.487

3.  Inhibition of the PI3 kinase/Akt pathway enhances doxorubicin-induced apoptotic cell death in tumor cells in a p53-dependent manner.

Authors:  Yusuke Fujiwara; Kei Kawada; Daiki Takano; Susumu Tanimura; Kei-ichi Ozaki; Michiaki Kohno
Journal:  Biochem Biophys Res Commun       Date:  2005-12-19       Impact factor: 3.575

Review 4.  Topoisomerase-targeting antitumor drugs.

Authors:  P D'Arpa; L F Liu
Journal:  Biochim Biophys Acta       Date:  1989-12-17

5.  Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Authors:  M C Alley; D A Scudiero; A Monks; M L Hursey; M J Czerwinski; D L Fine; B J Abbott; J G Mayo; R H Shoemaker; M R Boyd
Journal:  Cancer Res       Date:  1988-02-01       Impact factor: 12.701

6.  Matrix metalloproteinase-2 and -9 are induced differently by doxorubicin in H9c2 cells: The role of MAP kinases and NAD(P)H oxidase.

Authors:  Paolo Spallarossa; Paola Altieri; Silvano Garibaldi; Giorgio Ghigliotti; Chiara Barisione; Valeria Manca; Patrizia Fabbi; Alberto Ballestrero; Claudio Brunelli; Antonio Barsotti
Journal:  Cardiovasc Res       Date:  2005-10-06       Impact factor: 10.787

7.  Induction of 1C aldoketoreductases and other drug dose-dependent genes upon acquisition of anthracycline resistance.

Authors:  Zachary W Veitch; Baoqing Guo; Stacey L Hembruff; Adam J Bewick; Allan D Heibein; Jamei Eng; Stephanie Cull; David A Maclean; Amadeo M Parissenti
Journal:  Pharmacogenet Genomics       Date:  2009-06       Impact factor: 2.089

8.  Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines.

Authors:  C M Tsai; K T Chang; L H Wu; J Y Chen; A F Gazdar; T Mitsudomi; M H Chen; R P Perng
Journal:  Cancer Res       Date:  1996-01-01       Impact factor: 12.701

Review 9.  Individualized therapy in non-small-cell lung cancer: future versus current clinical practice.

Authors:  R Pérez-Soler
Journal:  Oncogene       Date:  2009-08       Impact factor: 9.867

10.  Role of drug transporters and drug accumulation in the temporal acquisition of drug resistance.

Authors:  Stacey L Hembruff; Monique L Laberge; David J Villeneuve; Baoqing Guo; Zachary Veitch; Melanie Cecchetto; Amadeo M Parissenti
Journal:  BMC Cancer       Date:  2008-11-03       Impact factor: 4.430
View more
  1 in total

1.  In vitro biophysical, microspectroscopic and cytotoxic evaluation of metastatic and non-metastatic cancer cells in responses to anti-cancer drug.

Authors:  Qifei Li; Lifu Xiao; Sitaram Harihar; Danny R Welch; Elizabeth Vargis; Anhong Zhou
Journal:  Anal Methods       Date:  2015-11-03       Impact factor: 2.896
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.